Ningning Song

Dr. Ningning Song


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
CPChongZhe Pei
ChongZhe Pei
YDYuxin Dong
Yuxin Dong
NSNingning Song
Ningning Song
Septic patients often face high mortality rates, influenced by various factors, including inflammation and nutritional status. This study investigates the relationship between the Advanced Lung Cancer Inflammation Index (ALI), an indicator of inflammation and nutritional status, and mortality rates (28-day, in-hospital, and ICU) in septic patients. We conducted a retrospective analysis using data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, focusing on septic patients. Our primary analysis tools were multivariate logistic regression and restricted cubic spline (RCS) to examine the association between ALI and mortality outcomes. Additionally, subgroup and sensitivity analyses were performed to validate the findings. The study included 3,739 septic patients. Results showed that higher ALI levels were significantly associated with reduced 28-day and in-hospital mortality rates. Specifically, a one-unit increment in natural log-transformed ALI was linked to a 16% reduced risk of 28-day mortality (p < 0.001) and a 12% reduced risk of in-hospital mortality (p = 0.002). These findings were consistent across different subgroups, confirming the stability of the results. Elevated ALI levels are associated with lower mortality rates in septic patients, suggesting ALI as a potential prognostic marker for this group. However, further large prospective studies are needed to corroborate these findings and explore the implications for clinical practice.

25 September 2019 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
NSNingning Song
Ningning Song
LZLingzhou Zhao
Lingzhou Zhao
MZMeilin Zhu
Meilin Zhu
JZJinhua Zhao
Jinhua Zhao
Triple negative breast cancer (TNBC), the most aggressive breast cancer type, is associated with high mortality and recurrence rates. An active-targeted strategy based on homing peptides is an effective approach to diagnose and treat cancer as it can deliver imaging agents or therapeutic drugs into desired tissues and accumulate less into off-target tissues. As a homing peptide, LyP-1 has shown properties of targeting, internalization, and proapoptosis to TNBC. In the study, we designed a Technetium-99m- (99mTc-) labeled LyP-1 and investigated its feasibility for targeted single-positron emission computed tomography (SPECT) imaging of TNBC. The results showed that the LyP-1 peptide had acceptable biocompatibility in the studied concentration range and could specifically bind to TNBC cells in vitro.99mTc-labeled LyP-1 showed high radiochemical purity and stability and could be used as a probe for targeted SPECT imaging of TNBC cells in vitro and in a TNBC tumor-bearing mouse model. Our findings indicate that this active-targeted strategy has great potential to be developed into a new imaging tool for TNBC diagnosis.

1 August 2023 in APL Materials
Verified
Journal Article
Open access
PDF file
NSNingning Song
Ningning Song
BLBo Li
Bo Li
DLDandan Li
Dandan Li
YYYunwen Yan
Yunwen Yan
Zr-based metal–organic frameworks (MOFs) using thiazolothiazole as an organic ligand exhibit excellent two-photon excited fluorescence performance, particularly in the generation of reactive oxygen species. In this study, a ZrTc nanoMOF was designed and modified with hyaluronic acid (HA) to provide good biocompatibility and cancer cell-specific targeting. In triple negative breast cancer (TNBC), the optimized composite ZrTc@HA exhibited considerable two-photon activity and excellent light-triggered O2·− generation ability at an excitation wavelength of 780 nm. ZrTc@HA can be used as a diagnostic probe for fluorescence imaging and as a therapeutic agent for photodynamic therapy (PDT) with no remarkable toxicity in vitro or in a subcutaneous tumor model in vivo. In summary, we developed a promising two-photon-activated ZrTc@HA for PDT in TNBC, with immense potential for advancements in monotherapy and synergistic phototherapy.

22 July 2025 in Menopause
Verified
Journal Article
Closed access
XXXinquan Mm Xi
Xinquan Mm Xi
CPChongzhe Pei
Chongzhe Pei
NSNingning Song
Ningning Song
Objective: Obesity and insulin resistance are major public health concerns, especially among perimenopausal women. Accurate estimates of their prevalence and analysis of trends are essential for informing policy decisions, guiding future research, and ultimately improving health outcomes in both perimenopausal and postmenopausal women. Methods: This study included 1,325 perimenopausal women aged 42-59 years from NHANES surveys conducted between 2003 and 2023. Eligibility was based on self-reports of at least one menstrual period in the previous 12 months. This study assessed the prevalence of and trends in general obesity, abdominal obesity, severe obesity, and insulin resistance among perimenopausal women in the United States. Results: From 2003 to 2023, the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance increased significantly, with rates increasing from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Logistic regression and Joinpoint analysis confirmed these upward trends. Statistical significance was consistent across the trends in mean BMI, waist circumference, and fasting blood insulin. Furthermore, significant disparities were observed in these trends across sociodemographic subgroups. Conclusions: From 2003 to 2023, there was a significant increase in the prevalence of obesity and insulin resistance among US perimenopausal women, with notable disparities across racial and ethnic groups. Further research is essential to assess the impact of public health interventions on these trends and develop targeted strategies to address the increasing prevalence of these conditions.

10 August 2024 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
YCYing Chen
Ying Chen
XMXinmin Meng
Xinmin Meng
KYKuan Yang
Kuan Yang
HWHanfei Wang
Hanfei Wang
CPChongZhe Pei
ChongZhe Pei
NSNingning Song
Ningning Song

21 November 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
NSNingning Song
Ningning Song
XXXinquan Xi
Xinquan Xi
KZKejian Zhang
Kejian Zhang
ZLZeyu Li
Zeyu Li
YKYang Kuan
Yang Kuan
CPChongzhe Pei
Chongzhe Pei
Women with autoimmune diseases (AIDs) experience chronic immune dysregulation and hormonal fluctuations, both of which may influence breast cancer risk. However, it remains unclear whether this risk is driven mainly by its treatment or the underlying disease, highlighting the need for integrating real-world data and genetic evidence. The FDA Adverse Event Reporting System (FAERS) were utilized to identify breast cancer safety signals among women with AIDs, analyzing 11,479 reports from 2004 to 2024. Disproportionality analyses using Reporting Odds Ratio (ROR) and Information Component (IC) were conducted. Then, we mapped these drugs to their target genes and performed mendelian randomization (MR) to assess their causal relationships with breast cancer. Finally, we investigated shared genetic architecture between breast cancer and AIDs using global and local genetic correlation, cross-trait meta-analysis, and transcriptome-wide association studies. We identified 13 immunosuppressive drugs (TNF inhibitors, interleukin inhibitors, and monoclonal antibodies), 3 immunostimulants and 16 adjunctive drugs associated with increased breast cancer reporting in patients with AIDs. The drugs with the highest case reports for positive disproportionality analysis were interferon beta-1a (N: 1731, IC [IC025] 1.56 [1.49]), natalizumab (798, 0.65 [0.54]), and infliximab (741, 0.64 [0.53]). MR results revealed causal links between 9 drug targets and breast cancer risk, such as FDPS (OR: 0.66, p: 1.33E-08), CALCRL (OR: 0.887, p: 4.77E-06) and PARP1 (OR: 1.051, p: 3.50E-06). Global genetic correlation identified significant shared heritability between breast cancer and 3 specific AIDs, including type 1 diabetes mellitus (rg: -0.242, p: 0.95E-4), ulcerative colitis (rg: 0.125, p: 0.29E-2), and migraine (rg: 0.078, p: 0.79E-2). Specifically, the most notable genetic overlap was observed between breast cancer and type 1 diabetes mellitus, with significant shared risk SNPs (rs12046289 and rs6679677) and susceptibility genes (ADCY3 and CENPO). Our study uncovered several immune-related drugs associated with increased breast cancer reporting in women with AIDs. This risk may be explained by several potential drug targets with causal roles, or by the shared genetic comorbidity between specific AIDs and breast cancer. These insights emphasize the need for tailored breast cancer surveillance and highlight potential molecular targets for intervention in vulnerable populations.